Beam Therapeutics CEO on CRISPR’s future, sickle cell research: The Endpoints Slack interview - Endpoints News

Even with last year's landmark approvals for genetic medicines in sickle cell disease, John Evans is convinced his startup can push the field further. Beam Therapeutics started 2024 by announcing it had dosed the first sickle cell patient with its base-edAds Links by Easy Branches
Play online games for free at games.easybranches.com

Guest Post Services www.easybranches.com/contribute